Mode
Text Size
Log in / Sign up
N/A N=60 Randomized Treatment

Recovering From Intimate Partner Violence Through Strengths and Empowerment (RISE)

Intimate Partner Violence · Self-efficacy

Enrolled (actual)
60
Serious AEs
8.3%
Results posted
Mar 2023
Primary outcome: Primary: Empowerment Via the Personal Progress Scale Revised — 129.82; 132.25; 146.13; 137.24 score on a scale — p=<.05

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
RISE (Behavioral); Information and referral condition (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
VA Office of Research and Development
Primary completion
Nov 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Empowerment Via the Personal Progress Scale Revised
129.82; 132.25; 146.13; 137.24; 148.07; 137.66 <.05 sig
PRIMARY
Self-efficacy Via the General Self-Efficacy Scale
28.7; 29.90; 33.33; 30.66; 34.07; 30.52 <.05 sig
PRIMARY
Valued Living Questionnaire
49.88; 48.88; 63.27; 53.44; 60.96; 57.23
PRIMARY
Patient Activation Measure (PAM-13)
65.89; 64.62; 76.5; 69.24; 75.5; 70.12
SECONDARY
PTSD Checklist for DSM-5
41.92; 39.97; 29.97; 36.97; 32.73; 32.13
SECONDARY
Center for Epidemiological Studies-Depression Scale
27.21; 24.50; 19.59; 22.76; 21.12; 19.72
SECONDARY
SF-12 Health Survey
3; 3; 3; 2; 3; 3
SECONDARY
Conflict Tactic Scales Revised
11.17; 11.67; 3.37; 4.93; 3.34; 2.8
SECONDARY
Physical, Mental and Social Service Care Use
8.27; 7.03; 6.15; 6.24; 4.62; 4.93
SECONDARY
Client Services Questionnaire (CSQ-8)
29.30; 25.07
SECONDARY
Patient Health Questionnaire
12.52; 10.60; 11.37; 12.01; 11.42; 9.69
SECONDARY
Safety Behaviors Checklist
12.87; 12.94; 13.04; 12.39; 9.4; 12.34
SECONDARY
Connor-Davidson Resilience Scale
25.43; 24.1; 29.67; 26; 29.65; 26.07
SECONDARY
Depression Anxiety Stress Scale- Anxiety Subscale
25.11; 23.4; 22.67; 22.98; 23.58; 21.22
SECONDARY
Coping Strategies Inventory - Short Form
26.42; 25.69; 27.30; 25.74; 26.92; 25.4
SECONDARY
Brief Semi-structured Interview to Assess Acceptability and Feasibility of the Intervention, With Perceived Helpfulness Rating.
23; 16; 6; 14; 0; 0

Summary

Intimate partner violence (IPV) is a major health concern for women Veterans. IPV is associated with numerous physical and mental health conditions. VHA is implementing IPV screening programs to identify female patients who experience past-year IPV. Despite strong evidence that screening increases detection of IPV, less is established about how to intervene following IPV disclosure in health care settings, in order to improve health outcomes. Existing healthcare-based interventions result in minimal effects on health and well-being, likely because they are too brief and generic. In response, the PI has developed Recovering from IPV through Strengths and Empowerment (RISE), based on the IPV-related health care needs and preferences of women Veterans. RISE is designed to be delivered in primary care and is an individualized, variable-length, modular-based intervention that addresses * safety planning; * education on the health effects of IPV and warning signs; * increasing coping skills and self-care; * enhancing social support; * making difficult decisions; and * connecting with resources. This study is aimed at refining and evaluating RISE for use with female VA patients who have experienced past-year IPV. This brief counseling intervention is intended to be administered in conjunction with primary care, as this is a frequent point of healthcare contact for women Veterans and where disclosure of IPV is most prevalent.

Eligibility Criteria

Inclusion Criteria

Participants will be eligible to participate if they:

  • Self-identify as a woman
  • Are at least 18 years of age
  • A patient at VA Boston Healthcare System
  • Self- reported that they have experienced past-year physical, sexual, or psychological IPV
  • Ability to understand study procedures in English
  • Not exhibiting symptoms of mania or psychosis
  • Not actively in suicidal crisis warranting imminent hospitalization

Exclusion Criteria

  • Any violation of inclusion criteria
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03261700). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search